Immune Tolerance Network (ITN)
At a Glance
- Status: Active Consortium
- Year Launched: 2010
- Initiating Organization: National Institutes of Health
- Initiator Type: Government
- Disease focus:
Allergy, Asthma, Autoimmune Diseases, Transplantations
- Location: North America
The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The organization’s mission is to accelerate the clinical development of immune tolerance therapies.
ITN is an organization born from the collective vision of NIAID and the tolerance research community. As such, the vision and the principles upon which the organization was founded are a reflection of the community itself.
The Statement of Values and Commitments clearly defines these principles and provides a framework that guides ITN in its activities. This commitment ensures that it will continue as a strong advocate for the community in an open and accessible manner.
ITN’s mission is to advance the clinical application of immune tolerance by performing high-quality clinical trials of emerging therapeutics integrated with mechanism-based research.
In particular, ITN aims to:
ITN is sponsored by NIAID, with support from the Juvenile Diabetes Research Foundation. Additional funding has also been provided through the special Type 1 diabetes appropriation overseen by the National Institute of Diabetes, Digestive and Kidney Diseases.
ITN’s data sharing policy is published on its website. The document includes ITN policies for when and how clinical, specimen, and mechanistic study data will be released to the public, including how such release will be limited to protect participant privacy. The ITN TrialShare web portal is the primary mechanism of data sharing and therefore the main focus of the policy.
ITN conducts research and clinical trials in the following areas: allergy and asthma, autoimmune disease, transplantation, and Type 1 diabetes. The research activities, including clinical trials that are looking for patients to enroll, for each disease are available on ITN’s website.
ITN’s accomplishments are as follows:
Sponsors & Partners
Office of the Director
Benaroya Research Institute
1201 Ninth Avenue
Seattle, WA 98101-2795
Gerald Nepom, M.D., Ph.D.
Research Funding, Application and Communication Inquiries
Philip Bernstein, Ph.D.
Executive Director, Strategic Review, Planning and Communications
Bioinformatics & TrialShare
Adam Asare, Ph.D.
Executive Director, Bioinformatics Group
Vince Carey, Ph.D.
Scientific Director, Bioinformatics Group